SCHEMBL947201

SCHEMBL947201

COc1ccc2[nH]cc(CN3CCN(C)CC3)c2c1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 6/20 0.69
MPO P05164 1/20 0.68
HTR2A P28223 2/20 0.65
HTR6 P50406 1/20 0.63
ASIC3 Q9UHC3 1/20 0.62
DRD2 P14416 5/20 0.61
DRD3 P35462 5/20 0.61
DRD4 P21917 3/20 0.61
GPR84 Q9NQS5 1/20 0.61
HTR1B P28222 2/20 0.60
ADRA2A P08913 1/20 0.58
ADRA2B P18089 1/20 0.58
ADRA2C P18825 1/20 0.58
ADRA1D P25100 1/20 0.58
ADRA1A P35348 1/20 0.58
ADRA1B P35368 1/20 0.58
HTR2B P41595 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19140382 0.90 HTR1A (0.65) HTR1AHTR2AASIC3DRD2DRD3
SCHEMBL5172365 0.89 HTR2A (0.74) HTR1AHTR2AHTR6ASIC3DRD2
SCHEMBL17533456 0.87 HTR1A (0.62) HTR1AHTR2AASIC3DRD2DRD3
SCHEMBL20629330 0.85 DRD2 (0.60) HTR1AHTR2AASIC3DRD2DRD3
SCHEMBL5198374 0.82 DRD3 (0.68) HTR1ADRD2DRD3DRD4ADRA2A
SCHEMBL4772684 0.82 KDM4E (0.69) HTR1AHTR2AHTR6DRD2DRD3
SCHEMBL13499605 0.81 MPO (1.00) HTR1AMPOHTR6DRD2DRD3
SCHEMBL947539 0.81 MPO (0.71) HTR1AMPOHTR2AHTR6DRD2
SCHEMBL947562 0.81 MPO (0.71) HTR1AMPOHTR2AHTR6ASIC3
SCHEMBL19252842 0.81 MPO (0.71) HTR1AMPOHTR6DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114642667-A Pure 5-HT6Combination of receptor antagonists with acetylcholinesterase inhibitors 苏文生命科学有限公司 2022-06-21 CN claimed
EP-3077375-B1 PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE SUVEN LIFE SCIENCES LTD (IN) 2017-07-19 EP claimed
US-9540321-B2 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate SUVEN LIFE SCIENCES LIMITED (IN) 2017-01-10 US claimed
US-20160297759-A1 PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE SUVEN LIFE SCIENCES LIMITED (IN) 2016-10-13 US claimed
EP-3077375-A1 PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE Suven Life Sciences Limited (IN) 2016-10-12 EP claimed
WO-2015083179-A1 PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE SUVEN LIFE SCIENCES LIMITED (IN) 2015-06-11 WO claimed
EP-4069232-A1 TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA PATIENTS Suven Life Sciences Limited (IN) 2022-10-12 EP disclosed
CN-114642667-A Pure 5-HT6Combination of receptor antagonists with acetylcholinesterase inhibitors 苏文生命科学有限公司 2022-06-21 CN disclosed
EP-3180001-B1 ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL) SULFONYL]-5-METHOXY-3- [(4-METHYL-1-PIPERAZINYL) METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE SUVEN LIFE SCIENCES LTD (IN) 2019-01-09 EP disclosed
EP-3077375-B1 PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE SUVEN LIFE SCIENCES LTD (IN) 2017-07-19 EP disclosed
EP-3077375-B1 PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE SUVEN LIFE SCIENCES LTD (IN) 2017-07-19 EP disclosed
US-9540321-B2 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate SUVEN LIFE SCIENCES LIMITED (IN) 2017-01-10 US disclosed
US-9540321-B2 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate SUVEN LIFE SCIENCES LIMITED (IN) 2017-01-10 US disclosed
US-7781476-B2 Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders SUVEN LIFE SCIENCES LIMITED (IN) 2010-08-24 US disclosed
EP-1581492-B1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2008-07-16 EP disclosed
US-20070142398-A1 Tetracyclic 3-substituted indoles having serotonin receptor affinity SUVEN LIFE SCIENCES LIMITED (IN) 2007-06-21 US disclosed
EP-1581538-B1 TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY SUVEN LIFE SCIENCES LTD (IN) 2007-02-28 EP disclosed
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2006-10-05 US disclosed
EP-1581538-A1 TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY Suven Life Sciences Limited (IN) 2005-10-05 EP disclosed
WO-2004055026-A1 TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY SUVEN LIFE SCIENCES LIMITED (IN) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142398-A1 Tetracyclic 3-substituted indoles having serotonin receptor affinity HTR3A, HTR3C, HTR3B HTR1A 4/4885MPO 4733/4885HTR2A 8/4885
US-20160297759-A1 PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE HTR6, HTR2A, HTR5A HTR1A 4/4885MPO 4264/4885HTR2A 2/4885
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them HTR3A, HTR3C, HTR2C HTR1A 6/4885MPO 4766/4885HTR2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.